Cinacalcet
- Generic Name
- Cinacalcet
- Brand Names
- Mimpara, Sensipar, Cinacalcet Mylan, Cinacalcet Accordpharma
- Drug Type
- Small Molecule
- Chemical Formula
- C22H22F3N
- CAS Number
- 226256-56-0
- Unique Ingredient Identifier
- UAZ6V7728S
- Background
Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
- Indication
For the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease who are on hemodialysis or peritoneal dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma.
- Associated Conditions
- Hypercalcemia, Secondary Hyperparathyroidism (SHPT)
- Associated Therapies
- -
Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?
- Conditions
- Interventions
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 110
- Registration Number
- NCT02227264
- Locations
- 🇸🇪
Karolinska University Hospital, Stockholm, Sweden
A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis
- Conditions
- Interventions
- First Posted Date
- 2014-05-08
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 62
- Registration Number
- NCT02133404
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
- Conditions
- Interventions
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 683
- Registration Number
- NCT01896232
- Locations
- 🇹🇷
Research Site, Izmir, Turkey
Influence of Cincalcet on Cognitive Functions in Healthy Human Subjects
- First Posted Date
- 2012-05-16
- Last Posted Date
- 2012-10-03
- Lead Sponsor
- Prof. Dominique de Quervain, MD
- Target Recruit Count
- 40
- Registration Number
- NCT01599962
- Locations
- 🇨🇭
University of Basel, Division of Cognitive Neuroscience, Basel, Switzerland
Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2011-10-06
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 67
- Registration Number
- NCT01447368
- Locations
- 🇭🇰
Queen Mary Hospital and Tung Wah Hospital, Hong Kong, Hong Kong
Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2011-02-04
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 14
- Registration Number
- NCT01290029
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Acute Effects of Cinacalcet on Arterial Stiffness and Ventricular Function in Hemodialysis Patients
- First Posted Date
- 2010-11-30
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- Laval University
- Target Recruit Count
- 23
- Registration Number
- NCT01250405
- Locations
- 🇨🇦
Karine Marquis, Québec, Quebec, Canada
Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis
- Conditions
- Interventions
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 312
- Registration Number
- NCT01181531
Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation
- Conditions
- Interventions
- First Posted Date
- 2010-08-10
- Last Posted Date
- 2015-04-28
- Lead Sponsor
- Josep M Cruzado
- Target Recruit Count
- 30
- Registration Number
- NCT01178450
- Locations
- 🇪🇸
Hospital Clinic de Barcelona, Barcelona, Spain
🇪🇸Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelone, Spain
Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism
- First Posted Date
- 2010-06-15
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 44
- Registration Number
- NCT01143987
- Locations
- 🇭🇰
Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, New Territories, Hong Kong
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.